PraXsyn Sales Approximately $11M for April; Up From $8.8M in March

PALO ALTO, Calif., May 5, 2014 -- PraXsyn Corporation (OTCQB:PAWS) announces that after reporting March sales of $8.8M, April sales have increased to approximately $11M. "We are excited about the growth in sales, and we are looking forward to continued growth," said Dan Wiesel CEO of PraXsyn. Additionally, PraXsyn has asked DBB McKennon to become the company's new auditor. With the business in rapid growth, we felt that a local auditor would be more efficient working with the PraXsyn management team.

The PAWS Pet Company’s (PraXsyn) 10K was filed this afternoon.

PALO ALTO, CA, April 23, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announces that its 10K filing was submitted to the SEC this afternoon. “We would like to thank our auditors and our financial team that worked around the clock to get it done,” said Dan Wiesel, CEO of The PAWS Pet Company. “With the 10K complete, we are looking forward to filing the 10Q which will incorporate the results of our new merger partner Mesa Pharmacy”.

March Sales at Wholly-Owned Subsidiary Mesa Pharmacy exceed $8.8M.

John Garbino and Ed Kurtz Join Board of Directors
Name change imminent.
PALO ALTO, CA, April 9, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announced it completed the merger of Pharmacy Development Corp. (PDC), the parent company of MESA Pharmacy, Inc. (“Mesa”) into PDC, Inc. (PDCINC), PAWS wholly-owned subsidiary on March 31, 2014.

Mesa Pharmacy prescription orders for February exceed $7.4 million. Sales continue to increase in line with expectations.

PALO ALTO, CA, March 12, 2014  - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that revised February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues, excluding allowances for returns and discounts, exceeding $7.4 Million Dollars.  Prescription orders for transdermal topical pain medications continue to rise.